Nicorette Icy White 4mg Chewing Gum
*Company:
KenvueStatus:
No Recent UpdateLegal Category:
Supply through general saleActive Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 03 January 2024
File name
ie-leaflet-nicorette-4mg-gums-2506.pdf
Reasons for updating
- Change to section 6 - marketing authorisation holder
- Change to section 6 - date of revision
Updated on 03 January 2024
File name
ie-spc-v11-nic-icywhite-4mg-gum-2506.pdf
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 10 - Date of revision of the text
Legal category:Supply through general sale
Updated on 14 August 2023
File name
ie-pl-nic-4mg-gums-2266.pdf
Reasons for updating
- Change to section 2 - what you need to know - contraindications
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 14 August 2023
File name
ie-spc-v10-nic-icywhite-4mg-gum-2266.pdf
Reasons for updating
- Change to section 4.3 - Contraindications
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category:Supply through general sale
Updated on 01 September 2020
File name
ie-mockup-pl-clean-bv1920.pdf
Reasons for updating
- Change to section 2 - what you need to know - contraindications
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 2 - interactions with other medicines, food or drink
- Change to section 3 - overdose, missed or forgotten doses
- Change to section 4 - possible side effects
- Change to section 4 - how to report a side effect
- Change to section 6 - what the product contains
- Change to section 6 - what the product looks like and pack contents
- Change to section 6 - date of revision
Updated on 01 September 2020
File name
NIZ02 BV1920 SPC v9.3.pdf
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.2 - Posology and method of administration
- Change to section 4.8 - Undesirable effects
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 6.1 - List of excipients
- Change to section 10 - Date of revision of the text
Legal category:Supply through general sale
Updated on 17 June 2019
File name
NIZ01 1692 SPC V8.0.pdf
Reasons for updating
- File format updated to PDF
Legal category:Supply through general sale
Updated on 04 July 2018
File name
NIZ01 1692 SPC V8.0.docx
Reasons for updating
- Company name change or merger
Legal category:Supply through general sale
Free text change information supplied by the pharmaceutical company
PA Transfer from McNeil Healthcare (Ireland) Ltd to Johnson & Johnson (Ireland) Ltd. Change in PA number. Note the address and contact details remain the same.
Updated on 04 July 2018
File name
Pages from ie-pl-4mg Gum combined-BV1613.pdf
Reasons for updating
- Change to name of manufacturer
Updated on 27 March 2018
File name
PIL_15755_346.pdf
Reasons for updating
- New PIL for new product
Updated on 27 March 2018
Reasons for updating
- Change to section 6 - marketing authorisation holder
Updated on 08 January 2018
Reasons for updating
- Change to section 4 - possible side effects
- Change to section 6 - marketing authorisation holder
- Change to section 6 - date of revision
Updated on 28 April 2016
Reasons for updating
- New SPC for new product
Legal category:Supply through general sale
Updated on 28 April 2016
Reasons for updating
- Change to section 4.8 - Undesirable effects
- Change to section 4.9 - Overdose
- Change to section 10 - Date of revision of the text
Legal category:Supply through general sale
Free text change information supplied by the pharmaceutical company
Section 4.8 added “Psychiatric Disorders – Abnormal Dreams* – Uncommon” to ADR table, and added text “*Identified only for formulations applied during the night”
Section 4.9 added text “Suspected nicotine poisoning in a child should be considered a medical emergency and treated immediately” and “If excessive amount of nicotine is swallowed, activated charcoal reduces the gastrointestinal absorption of nicotine”
Section 10 replaced date with “April 2016”
Updated on 27 April 2016
Reasons for updating
- Change to storage instructions
- Change to side-effects
- Change to date of revision
Updated on 10 December 2015
Reasons for updating
- Change to section 6.1 - List of excipients
- Change to section 6.5 - Nature and contents of container
Legal category:Supply through general sale
Free text change information supplied by the pharmaceutical company
Microcrystalline updated to microcrystalline wax
Section 6.5
PVC/PVDC/Al Blister packed strips each containing 6, 10 or 15 pieces supplied in packs of 10, 12, 15, 30, 105 and 210 pieces.
Updated on 14 August 2015
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.8 - Undesirable effects
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 10 - Date of revision of the text
Legal category:Supply through general sale
Free text change information supplied by the pharmaceutical company
4.2 – the following information was added
Administration of nicotine should be stopped temporarily if any symptoms of nicotine excess occur. Nicotine intake should be decreased by lowering dosing frequency if nicotine excess symptoms persist (see Section 4.9).
Section 4.4 – additional warnings added:
The benefits of quitting smoking outweigh any risks associated with correctly administered nicotine replacement therapy (NRT).
A risk-benefit assessment should be made by an appropriate healthcare professional for patients with the following conditions:
· Dependent smokers with a recent myocardial infarction, unstable or worsening angina including Prinzmetal’s angina, severe cardiac arrhythmias, recent cerebrovascular accident, and/or who suffer with uncontrolled hypertension should be encouraged to stop smoking with non-pharmacological interventions (such as counselling). If this fails, Nicorette Invisi Patch may be considered but as data on safety in this patient group are limited, initiation should only be under close medical supervision.
· Diabetes Mellitus. Patients with diabetes mellitus should be advised to monitor their blood sugar levels more closely than usual when smoking is stopped and NRT is initiated, as reductions in nicotine-induced catecholamine release can affect carbohydrate metabolism.
· Renal and hepatic impairment: Use with caution in patients with moderate to severe hepatic impairment and/or severe renal impairment as the clearance of nicotine or its metabolites may be decreased with the potential for increased adverse effects.
· Phaeochromocytoma and uncontrolled hyperthyroidism: Use with caution in patients with uncontrolled hyperthyroidism or phaeochromocytoma as nicotine causes release of catecholamines.
· Gastrointestinal Disease: Nicotine may exacerbate symptoms in patients suffering from oesophagitis, gastric or peptic ulcers and NRT preparations should be used with caution in these conditions.
· Smokers who wear dentures may experience difficulties in chewing Nicorette Gum. The chewing gum may stick to, and may in rare cases damage dentures.
Transferred dependence: Nicotine in any dose form is capable of inducing a dependence syndrome after chronic use and is highly toxic after acute use. However, dependence with Nicorette 2mg Gum is a rare side-effect and is both less harmful and easier to break than smoking dependence.
Danger in children: Doses of nicotine tolerated by smokers can produce severe toxicity in children that may be fatal. Products containing nicotine should not be left where they may be handled or ingested by children, see section 4.9 Overdose.
Section 4.5 – information on possible interaction with adenosine added:
Nicotine may possibly enhance the haemodynamic effects of adenosine i.e. increase in blood pressure and heart rate and also increased pain response (angina-pectoris type chest pain) provoked by adenosine administration.
Section 4.6 – information updated:
Women of childbearing potential/ contraception in males and females
In contrast to the well-known adverse effects of tobacco smoking on human conception and pregnancy, the effects of therapeutic nicotine treatment are unknown. Thus, whilst to date no specific advice regarding the need for female contraception has been found to be necessary, the most prudent state for women intending to become pregnant is to be both non-smoking, and not using NRT.
Whilst smoking may have adverse effects on male fertility, no evidence exists that particular contraceptive measures are required during NRT treatment by males.
Pregnancy:
Smoking during pregnancy is associated with risks such as intra-uterine growth retardation, premature birth or stillbirth. Stopping smoking is the single most effective intervention for improving the health of both pregnant smoker and her baby. The earlier abstinence is achieved the better.
Nicotine passes freely to the foetus and affects its breathing movements and circulation. The effect on the circulation is dose-dependent.
Therefore, the pregnant smoker should always be advised to stop smoking completely without the use of nicotine replacement therapy. The risk of continued smoking may pose a greater hazard to the foetus as compared with the use of nicotine replacement therapy products in a supervised cessation programme. Use of Nicorette Gum should only be initiated after advice from a physician.
Lactation:
Nicotine passes freely into breast milk in quantities that may affect the child even in therapeutic dose. Nicorette Gum should therefore be avoided during breast-feeding.
Should smoking cessation not be achieved, use of the Nicorette Gum by breast feeding smokers should only be initiated after advice from a health care professional.
Fertility
In females tobacco smoking delays time to conception, decreases in-vitro fertilization success rates, and significantly increases the risk of infertility.
In males tobacco smoking reduces sperm production, increases oxidative stress, and DNA damage. Spermatozoa from smokers have reduced fertilizing capacity.
The specific contribution of nicotine to these effects in humans is unknown.
Section 4.8 – additional AEs added, please refer to the SPC for full details
SNAS 1352
Updated on 13 August 2015
Reasons for updating
- Change to warnings or special precautions for use
- Change to side-effects
- Change to drug interactions
- Change to date of revision
- Addition of information on reporting a side effect.
Updated on 17 December 2014
Reasons for updating
- Discontinuation of one or more strengths
- Correction of spelling/typing errors
Updated on 04 July 2014
Reasons for updating
- PIL retired pending re-submission
- Change to dosage and administration
Updated on 11 June 2013
Reasons for updating
- New individual PIL (was previously included in a combined PIL)
Updated on 11 January 2013
Reasons for updating
- Change to section 4.8 - Undesirable effects
Legal category:Supply through general sale
Free text change information supplied by the pharmaceutical company
Updated on 06 February 2012
Reasons for updating
- Change to section 6.1 - List of excipients
Legal category:Supply through general sale
Free text change information supplied by the pharmaceutical company
Updated on 22 August 2011
Reasons for updating
- Change to section 4.1 - Therapeutic indications
Legal category:Supply through general sale
Free text change information supplied by the pharmaceutical company
Updated on 13 August 2010
Reasons for updating
- New SPC for new product
Legal category:Supply through general sale